ASTEX PHARMACEUTICALS, Cambridge, United Kingdom Read more
Dr David REES
David Rees joined the biotech company, Astex in 2003 and is Senior Vice President, Chemistry. Astex are pioneers of Fragment Based Drug Discovery and have progressed several compounds into clinical trials. Prior to Astex he had 19 years’ experience at Parke-Davis, Organon and AstraZeneca, Sweden.
David is a co-inventor of the anaesthetic drug Sugammadex (Bridion) which is marketed by Merck in over 40 countries. He is on the team that was awarded the Royal Society of Chemistry Malcolm Campbell Prize for this research.
David is a co-author of over 100 publications and patents and served as President of the Organic Division of the Royal Society of Chemistry (2010-2013). He is currently visiting Professor at Newcastle University and Council Member of the Royal Society of Chemistry (2015-2019).
Heterocycles and Medicinal Chemistry: the Importance of Innovative Synthesis
Tony leads Worldwide Research & Development’s Medicinal Sciences, a group that encompasses the small molecule and large molecule partner lines that enable and accelerate Pfizer’s end-to-end portfolio to deliver medicines and vaccines to patients.
Prior to this appointment,Tony served as the the head of Worldwide Medicinal Chemistry. Tony also served as Head of Chemistry and Exploratory Medicinal Sciences in Sandwich from February 2007 and Head of Chemistry from April 2004. Tony joined Pfizer as a Scientist in the Department of Discovery Chemistry at Sandwich in 1992. Over the period of the next 8 years he made a number of contributions to the delivery of development candidates in various projects from within the Sexual Health, Urology, and Gastrointestinal Therapeutic Areas. He was appointed to the post of Manager in 1999 with responsibility for Anti-Infectives Chemistry and played a leading role in the discovery of Maraviroc, a CCR5 antagonist for the treatment of HIV, for which he was awarded the RSC Malcolm Campbell Prize in 2005, and was a co-recipient of the ACS Heroes of Chemistry Prize, the Prix Galien USA and Scrip Awards in 2008 and the PhRMA Discoverers Award in 2010. This period of time also saw Tony leading the team that discovered Lersivirine a new non cross resistant non nucleoside reverse transcriptase inhibitor that is currently in Phase II. In recognition of these achievements Tony was awarded the UCB Ehrlich Prize for excellence in medicinal chemistry by the EFMC in 2010.
Tony received his BSc in 1987 and PhD in 1990 in chemistry from the University of Newcastle upon Tyne, before completing post-doctoral studies with Professor Steven Ley, FRS at Imperial College in London working on the total synthesis of azadirachtin, one of the most complex molecules ever to have been synthesized, and a project that has only recently been completed.
Tony has active interests in many areas of medicinal chemistry and has held positions on a number of UK funding council review boards such as the BBSRC and EPSRC. He was elected to EPSRC Council in 2010. Tony is also co-editor in chief of the new RSC journal, Medicinal Chemistry Communications, and was editor of volume 41 of Annual Reports in Medicinal Chemistry in 2006. Tony is an author or inventor on more than 50 scientific publications and patents and has given invited lectures at a number of International Conferences on Medicinal Chemistry. Lastly, Tony is a Visiting Professor at the University of Newcastle upon Tyne.
Novel Derivatives of the Tspo Ligand Dpa-714 For in Vivo Pet Imaging of Neuroinflammation (OC04)
Fanny CACHEUX got her Engineer Diploma with a speciality in Organic and Therapeutic Chemistry in 2013 at the Chemistry Engineering School in Mulhouse in France. During the engineering school she performed three internships in European and French laboratories (two months in the group of Pr Breit at the university of Freiburg-im-Breisgau in Germany, one year in Actelion Pharmaceuticals in Allschwil (Switzerland) and six months at the CEA in France) at the interface of medicinal chemistry and biology. Then, she realized her PHD dedicated to the synthesis of new ligands for neuroinflammation imaging by Positron Emission Tomograghy, at the CEA in Orsay (France). She will obtain her PhD degree in October 2016.
Experimental Platform for Characterization and High-Throughput Screening of Acetylcholinesterase Inhibitors Winner of the young medicinal chemist meeting in Poland (CP14)
Dr Piotr DRACZKOWSKI
UNIVERSITY OF LUBLIN, Lublin, Poland
Drug Design, Synthesis and Biological Evaluation of Antiretroviral and Anticancer Agents Winner of the young medicinal chemist meeting in Italy (CP02)
Dr Valeria FAMILGLINI
UNIVERSITY OF ROME, Rome, Italy
Drugging the Undrugguble: Targeting Challenging E3 Ligases Winner of the young medicinal chemist meeting in Spain (CP04)
Dr Carles GALDEANO
UNIVERSITAT DE BARCELONA, Barcelona, Spain
Purine Mimicking 3'-Ethynylribofuranose Nucleosides: New Opportunities for an Old Sugar Modification Winner of the young medicinal chemist meeting in Belgium (KVCV) (CP13)
Mr Fabian HULPIA
UGENT, Ghent, Belgium
Development of Highly Selective and Reversible Diacylglycerol Lipase Inhibitors Winner of the young medicinal chemist meeting in The Netherlands (CP05)
Dr Freek JANSSEN
LEIDEN UNIVERSITY, Nijmegen, The Netherlands
Development of Potent, Cell-Active Inhibitors of the
Mycobacterium Tuberculosis Cholesterol Oxidase
Ms Madeline KAVANAGH
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom Read more
Ms Madeline KAVANAGH
Madeline completed her undergraduate Bachelor and Master’s degrees at the University of Sydney, Australia, under the supervision of Professor Michael Kassiou. Her diploma and MSc. research focused on the development of kinase inhibitors as disease modifying therapeutics for Parkinson’s disease. After receiving a Commonwealth Scholarship in 2013, she joined the research group of Professor Chris Abell at the University of Cambridge for her PhD. Her doctoral research concentrates on studying the family of cytochrome P450 enzymes expressed by Mycobacterium tuberculosis and developing small molecule inhibitors to target these enzymes. Madeline’s research encompasses fragment-based drug discovery, medicinal chemistry, biophysical, biochemical and molecular biology techniques, which she uses to understand the relationships between P450 enzymes and their potential as drug targets for tuberculosis. Madeline was selected as a one of the ACS’s Young Chemist Crossing Borders in 2015 and received an honourable mention for her doctoral work in 2016 from the Association of British Turkish Academics.
New Avenues in Protein Labeling - Exploiting Dna for Directing Chemical Reactions Winner of the young medicinal chemist meeting in Denmark (CP01)
Dr Anne Louise Bank KODAL
NOVO NORDISK, Bagsværd, Denmark
Functional Lipidomics-Based Lead Discovery Reveals Novel Role of Phospholipids in Vitamin A Signaling Winner of the young medicinal chemist meeting in Germany (CP06)
Dr Andreas KOEBERLE
UNIVERSITY OF JENA, Jena, Germany
Design and Synthesis of 2,2'-Diindolylmethanes to Selectively Target Certain G-Quadruplex Dna Structures Winner of the young medicinal chemist meeting in Sweden (CP08)
Dr Madeleine LIVENDAHL
UMEA UNIVERSITY, Umeå, Sweden
Discovery of Cct251921: A Potent, Selective and Orally Bioavailable Small Molecule Modulator of the
Mediator Complex-Associated Kinases Cdk8 and Cdk19 (OC02)
Dr Aurelie MALLINGER
INSTITUTE OF CANCER RESEARCH, London, United Kingdom Read more
Dr Aurelie MALLINGER
I carried out my PhD at the CEA (Commissariat à l'Energie Atomique) in France, working on natural product synthesis. After completion of a one year post-doc at the University of Oxford, I joined the Institute of Cancer Research (ICR) in London. I am a medicinal chemist involved in multidisciplinary projects and I have worked mainly on the discovery of small molecule inhibitors of Wnt signalling in close collaboration with Merck KGaA, Darmstadt (Germany).
Stable, Effective, and Selective Anticancer Phenolato Titanium(Iv) Complexes Winner of the young medicinal chemist meeting in Israel (CP09)
Mrs Sigalit MEKER
THE HEBREW UNIVERSITY OF JERUSALEM, Jerusalem, Israel
Design, Synthesis and Biological Evaluation of Selective CDK Inhibitors based on Flavopiridol Structure Winner of the young medicinal chemist meeting in Greece (CP07)
Dr Nikitia MEXIA
UNIVERSITY OF ATHENS, Leeds, United Kingdom
How to Design Cell Permeable Non-Peptidic Macrocycles (OC03)
Dr Björn OVER
MACROCYCLE ADME, BEYOND RO5 AND NATURAL PRODUCT-FRAGMENTS, Landvetter, Sweden Read more
Dr Björn OVER
Björn Over studied chemistry at the universities of Marburg (Germany) and Uppsala (Sweden). He performed his diploma thesis on fragment-based drug design under the supervision of Prof. Gerhard Klebe and earned his PhD at the Max-Planck Institute for Molecular Physiology (Dortmund/Germany) for his work on natural product-derived fragments under the direction of Prof. Herbert Waldmann. Since 2013 he was a postdoc at AstraZeneca R&D Gothenburg (Sweden). In 2014 Björn received the “Klaus-Grohe Preis für Medizinische Chemie”, awarded by the German chemical society (“GDCh”). Björn co-authored reviews on cell permeability and bioavailibility at the border of or beyond the 'rule of 5'. His latest research was focused on the ADME properties and design of cell permeable non-peptidic macrocycles. Currently he is enjoying his parental leave and prepares for new challenges.
Glyco-Conjugated Photosensitizers: From Synthesis to Validation in Cancer Photodynamic Therapy Winner of the young medicinal chemist meeting in Portugal (CP10)
Ms Patricia PEREIRA
UNIVERSIDADE DE AVEIRO, Aveiro, Portugal
New 3d-Scaffolds for Fragment-Based Lead Discovery (Fbld): Exploration of Chemical Space Using Functionalized Spirohydantoins Winner of the young medicinal chemist meeting in France (CP11)
Mr Hugues PREVET
LABORATORY U1177 - UNIVERSITY OF LILLE, Lille, France
Antimalarial Drug Discovery: Exploring the Mep Pathway Winner of the young medicinal chemist meeting in the United Kingdom (CP03)
Ms Kathryn PRICE
UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom
Discovery Of Novel Atpase Inhibitors Of Dna Gyrase And Topoisomerase Iv Starting From Marine Sponge Alkaloid Oroidin Winner of the young medicinal chemist meeting in Slovenia (CP12)